CVS Health (NYSE:CVS) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened

CVS Health Corporation (NYSE:CVS) crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $88.80 and traded as low as $87.88. CVS Health shares last traded at $88.5390, with a volume of 9,547,546 shares changing hands.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported Q3 adjusted earnings of $2.09 per share, above the $1.65 consensus estimate, while revenue rose 5.4% year over year to $108.4 billion. Management raised its 2026 adjusted EPS outlook to at least $8.20 from a prior range of $7.90–$8.10. CVS Q3 results and guidance
• Neutral Sentiment: The company plans to separate its retail pharmacy business from its health benefits, pharmacy-benefit and care operations, creating two publicly traded companies by the first half of 2028. CVS says the businesses could gain focus and strategic flexibility, though the separation is still more than a year away. CVS breakup plan
• Negative Sentiment: The breakup announcement appears to be the main overhang: investors are reacting warily to CVS reversing its vertically integrated strategy, including the Aetna combination, despite the earnings beat. The scale and complexity of unwinding the businesses may be fueling uncertainty around execution and the value of the new structure. Market reaction to CVS split plan

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CVS shares. Wall Street Zen lowered CVS Health from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 19th. UBS Group set a $110.00 price target on CVS Health in a research report on Wednesday. JPMorgan Chase & Co. increased their price target on CVS Health from $111.00 to $118.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 price target on shares of CVS Health in a research note on Wednesday, September 9th. Finally, TD Cowen restated a “buy” rating on shares of CVS Health in a research report on Wednesday. Twenty-two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $109.46.

CVS Health Trading Down 12.6%

The firm has a market cap of $102.19 billion, a price-to-earnings ratio of 11.66, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The firm’s fifty day moving average is $90.82 and its 200-day moving average is $88.86.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.65 by $0.44. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $108.40 billion for the quarter, compared to analysts’ expectations of $104.69 billion. During the same quarter in the prior year, the firm posted $1.60 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Equities analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd were issued a $0.6650 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date was Thursday, October 22nd. CVS Health’s payout ratio is presently 70.37%.

Hedge Funds Weigh In On CVS Health

Institutional investors have recently added to or reduced their stakes in the business. Kilter Group LLC acquired a new stake in CVS Health in the second quarter worth $27,000. J.Safra Asset Management Corp bought a new stake in CVS Health in the second quarter valued at approximately $30,000. Beaird Harris Wealth Management LLC boosted its stake in CVS Health by 201.0% during the second quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock valued at $30,000 after buying an additional 195 shares during the last quarter. Timbuktu Capital Management LLC purchased a new position in CVS Health during the 2nd quarter valued at approximately $31,000. Finally, Dunhill Financial LLC purchased a new position in CVS Health during the 2nd quarter valued at approximately $32,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Company Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.